Related Experiment Video

Updated: Oct 2, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Intravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient

Elyse J Zelunka1

  • 1Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. elyse.zelunka@sickkids.on.ca

Pharmacotherapy
|March 20, 2002
PubMed

Insights

This case study highlights a drug interaction between intravenous cyclosporine and rifampin in a pediatric bone marrow transplant patient. The interaction led to subtherapeutic cyclosporine levels, impacting treatment efficacy and graft-versus-host disease management.

Area of Science:

  • Pediatric Hematology Oncology
  • Pharmacology
  • Infectious Diseases

Background:

  • Bone marrow transplantation (BMT) is a critical treatment for pediatric cancers like chronic myelogenous leukemia (CML).
  • Cyclosporine is an essential immunosuppressant used post-BMT to prevent graft-versus-host disease (GVHD).
  • Staphylococcus aureus bacteremia is a serious complication in immunocompromised patients, including those undergoing BMT.

Observation:

  • A 10-year-old girl with CML developed S. aureus bacteremia post-BMT, requiring broad-spectrum antibiotics.
  • Intravenous rifampin was added to treat persistent fever and neutropenia.
  • Subtherapeutic cyclosporine levels were noted despite dose adjustments, coinciding with rifampin administration.

Findings:

  • The addition of intravenous rifampin to the patient's antibiotic regimen coincided with persistently subtherapeutic cyclosporine blood levels.
  • Cyclosporine levels normalized after rifampin discontinuation, suggesting a drug interaction.
  • The patient developed grade II graft-versus-host disease, which responded to methylprednisolone.

Implications:

  • This case is the first to document an intravenous cyclosporine-rifampin interaction causing subtherapeutic cyclosporine levels in a pediatric BMT patient.
  • Clinicians must be vigilant for potential drug interactions between immunosuppressants and antibiotics in pediatric BMT recipients.
  • Understanding such interactions is crucial for optimizing GVHD prophylaxis and treatment, and for improving patient outcomes post-transplant.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...